chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 10.0
Sex: M
Vaccine: DTAP, DTAP, TDAP, TDAP
Symptoms: Medication error, No adverse event, Wrong product administered
Clinical narrative: A patient received DTaP, DAPTACEL instead of TdaP, ADACEL, no AE; Initial information regarding an unsolicited valid non-serious case was received from other healthcare professional via Medical Information (Reference number-00581241) and transmitted to Sanofi on 28-Apr-2021.  This case involves a 10-year-old male patient who received 0.5 mL dose of suspect DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL] (lot C5621AA and expiry date: 23-May-2021) via an intramuscular route in the left arm and a dose of DIPHTHERIA VACCINE TOXOID, PERTUSSIS VACCINE ACELLULAR, TETANUS VACCINE TOXOID [DTAP] (lot number and expiry date not reported) via an unknown route in an unknown administration site for prophylactic vaccination instead of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] and DIPHTHERIA VACCINE TOXOID, PERTUSSIS VACCINE ACELLULAR, TETANUS VACCINE TOXOID [TDAP] on 28-Apr-2021 (wrong product administered).  The patient's medical history, past medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included MEASLES VACCINE, MUMPS VACCINE, RUBELLA VACCINE (MMR) and MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) (MENACTRA) for prophylactic vaccination.  This was a case of actual medication error due to wrong vaccine administered (latency was same day).   At the time of reporting, no adverse event reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 1.25
Sex: F
Vaccine: DTAPIPVHIB
Symptoms: Expired product administered
Clinical narrative: 15 month old female patient was administered expired dose of PENTACEL, no AE; Initial information received on 30-Apr-2021 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 15 month old female patient who was administered expired dose of DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL] (expired product administered).  Medical history, medical treatment, concomitant medication, vaccination and family history were not provided.   On 15-Apr-2021, the patient received a 0.5 ml dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE (lot UJ230AAA and expiry date: 04-Apr-2021) (Frequency: Once) via an unknown route at an unknown administration site for prophylactic vaccination.  It was a case of actual medication error due to expired vaccine used (latency on same day).  It was also reported that nurse asking if there is a time frame that they should wait before repeating the PENTACEL dose. Additional Description of event adverse events: Caller a nurse, stated she has questions regarding expired PENTACEL that was administered to a patient. No additional information was provided. Caller requested a call back to her mobile number today. The lot number and expiration date that they previously provided was from the box (PENTACEL). They do not have the patient date of birth with me. They do not have the route and site, concomitant vaccinations. No further information was provided. Note: The expiration date was previously documented in the Expiration Date field as 01Apr2021, but the nurse stated during call that the PENTACEL expired on 04Apr2021. Reporter relationship: health care professional (HCP) Product used: used   At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 1.25
Sex: F
Vaccine: HIBV
Symptoms: Expired product administered
Clinical narrative: patient received an expired dose of ACT-HIB, no AE; Initial information regarding an unsolicited valid non-serious case was received from the other healthcare professional via Medical Information (Reference number- 00585968) and transmitted to Sanofi on 03-May-2021.  This case involves a 15 month old female patient who was administered a 0.5 ml expired dose of suspect HIB (PRP/T) VACCINE [ACT-HIB] (lot number:UJ120AAB; expiry date: 22-Jan-2021; Strength: standard) via intramuscular route in left thigh site for prophylactic vaccination on 06-Apr-2021(expired product administered).  Medical history, medical treatment(s), past vaccination(s) and family history were not provided.  The patient's concomitant vaccinations included DIPHTHERIA VACCINE TOXOID, PERTUSSIS VACCINE ACELLULAR, TETANUS VACCINE TOXOID (DTAP) in left thigh for prophylactic vaccination.  It was a case of an actual medication error due to expired vaccine used (latency same day).  The reporter wanted to know what to do.  At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 1.0
Sex: M
Vaccine: HIBV
Symptoms: Product preparation issue
Clinical narrative: patient received a dose of ACTHIB which was reconstituted with sterile water; Initial information was received on 04-May-2021 regarding an unsolicited non-valid non-serious case from other health professional (inquiry number: 00587326).  It was reported that 0.5 mL of HIB (PRP/T) VACCINE [ACT-HIB] (lot number: UJ357AA and expiry date not reported) was administered to a one-year-old male patient which was reconstituted with sterile water via an unknown route at an unknown administration site for prophylactic vaccination (product preparation issue).  It was a case of actual medication error due to inappropriate reconstitution technique.  At the time of report, no adverse event reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 13.0
Sex: M
Vaccine: IPV
Symptoms: Incorrect dose administered, Medication error
Clinical narrative: a patient received 2.5mL of IPOL; Initial information was received on 04-May-2021 regarding an unsolicited non-valid non-serious case from other health professional (Inquiry number: 00587508).  It was reported that a 13-year-old patient received 2.5ml of IPV (VERO) [IPOL] (lot number: R1F97 and expiry date: 03-Oct-2021) (suspension for injection) via an unknown route at an unknown administration site of prophylactic vaccination (overdose).  It was a case of actual medication error due to vaccine overdose.  At the time of report, no adverse event reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 18.0
Sex: M
Vaccine: TYP
Symptoms: Expired product administered, No adverse event
Clinical narrative: 18 year old male patient received an expired dose of Typhim vaccine with no reported adverse event; Initial information received on 05-May-2021 regarding an unsolicited valid non-serious case received from a physician via Other Health Care Professional.  This case involves a 18 year old male patient who was administered expired dose of TYPHOID VI POLYSACCHARIDE VACCINE [TYPHIM VI] (expired product administered).  Medical history, medical treatment, vaccination and family history were not provided.  Concomitant medications included INFLUENZA VACCINE (INFLUENZA VACCINE) and TETANUS VACCINE (TETANUS VACCINE) for Immunisations.  On 24-Apr-2021, the patient received a 0.5 ml dose of suspect TYPHOID VI POLYSACCHARIDE VACCINE (lot R1B743M and expiry date: 23-Mar-2021) (Injection) (Frequency: Once) via an intramuscular route in the right arm for prophylactic vaccination.  It was a case of actual medication error due to expired vaccine used (latency on same day).  It was also reported that Reporter relationship: health care professional (HCP); Product used: used   At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 0.25
Sex: M
Vaccine: FLU4
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: A 3-month old male received a dose of the Fluzone Quadrivalent, with no reported adverse event; Initial information received on 05-May-2021 regarding an unsolicited valid non-serious case received from a physician  via Other Health Care Professional.  This case involves a three month old male patient who received INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT] (Product administered to patient of inappropriate age).  Medical history, medical treatment, concomitant medication, vaccination and family history were not provided.  On 05-May-2021, the patient received a 0.5 ml dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (lot UJ559AC and expiry date: 30-Jun-2021) (Frequency once) via an intramuscular route at an unknown administration site for prophylactic vaccination.  It was a case of actual medication error due to inappropriate age at vaccine administration (same day latency).  It was also reported that nurse Manager states that they administered FLUZONE QUAD (Prefilled) to a 3 month old. Is there anything that they should do next other than report it. Reporter relationship: health care professional (HCP); Product used: used First time product used: yes still using product: no.  At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: FLU4
Symptoms: Occupational exposure to product, Skin laceration, Syringe issue
Clinical narrative: A syringe collar broke when a staff member was vaccinating a patient with a vaccine, slicing the staff members finger.; A syringe collar broke when a staff member was vaccinating a patient with a vaccine, slicing the staff members finger.; This spontaneous case from the  was received on 29-Sep-2020 from other non-health professional via Product Technical Complaint (PTC) group and concerned a staff member of unknown age and gender.  The patient's medical history and concomitant medications were not reported.   On an unknown date, when a staff member was vaccinating a patient with Afluria Quadrivalent (influenza vaccine), a syringe collar broke and sliced the staff member's finger (explicitly coded as 'Syringe broke'). The device associated with Afluria Quadrivalent was Luer Lok syringe. The batch number reported was P100230205.  The outcome of event 'laceration of finger' was not reported.  The reporter did not provide a causality assessment to Afluria Quadrivalent.  This case has been entered onto manufacturing quality assurance tracking database and allocated reference number 1067172.  An investigation into batch P100230205 revealed that the most probable root cause of broken finger flange on was due to packaging equipment at the fill/finish facility. Shipping of the product was also a possible root cause for the event, as it could not be completely ruled out. Since the packaging line was the most likely root cause, the root cause had been assigned as 'Equipment Malfunction' and the complaint was justified. It was concluded that there was no requirement for any market action based on all information received, as there was no patient safety risk and the overall defect rate for broken finger flanges is 1 Defect/Million Syringes distributed. No additional actions were required for Afluria PFS Drug Product or for batch P100230205.  Additional information was received on 10-Nov-2020 from manufacturing quality assurance department: Quality Assurance Investigation Results were provided. Batch number was added. Narrative was amended accordingly.  Company comment: A syringe collar broke when a staff member was vaccinating a patient with Afluria Quadrivalent, slicing the staff members finger. Laceration was a result of syringe issue making causality unrelated to the product, while device issue was assessed as unrelated per company conventions. The causality for the events of 'laceration of finger' and 'syringe broken' were assessed as related to device Luer Lok syringe.; Sender's Comments: A syringe collar broke when a staff member was vaccinating a patient with Afluria Quadrivalent, slicing the staff members finger. Laceration was a result of syringe issue making causality unrelated to the product, while device issue was assessed as unrelated per company conventions. The causality for the events of 'laceration of finger' and 'syringe broken' were assessed as related to device Luer Lok syringe.
Sex: F
Vaccine: FLU4
Symptoms: Occupational exposure to product, Skin laceration, Syringe issue
Clinical narrative: I went to administer a flu shot and the glass ring that holds the plunger broke and cut my thumb; I went to administer a flu shot and the glass ring that holds the plunger broke and cut my thumb; This spontaneous case from  was received on 20-Oct-2020 from pharmacist via manufacturing quality assurance (product technical complaint (PTC) reference number: 1068610) and concerned a female nurse of unknown age.   The patient's medical history and concomitant medications were not reported.     On an unknown date, the nurse went to administer Afluria Quadrivalent flu shot (influenza vaccine, dose, route of administration, anatomical location: not reported) to the patient and the glass ring that held the plunger broke (explicitly coded as 'Syringe issue') and cut her thumb. The nurse continued to give the full shot to the patient as the needle was already in his arm. The device assocated with Afluria Quadrivalent was luer lok. The batch number reported was P100257535.   The full dose was administered to the patient. There was no leakage and the vaccine were stored in the refrigerator, as reported.   The outcome of event 'laceration of thumb' was not reported.  The reporter did not provide causality assessment to Afluria Quadrivalent. The reporter assessed the events as related to device luer lok.   Quality assurance investigation (QAI) of Afluria Quadrivalent vaccine, batch number reported as P100257535, (PTC number: 1067455) determined the most probable root cause of broken finger flange on 1 syringe in Afluria_P100257535 in the 2020/2021 campaign was due to packaging equipment at the fill/finish facility. Shipping of the product was also a possible root cause for the event, as it could not be completely ruled out. Since the packaging line was the most likely root cause, the root cause had been assigned as 'Equipment Malfunction' and the complaint was justified.  Additional information received on 04-Dec-2020 from manufacturing quality assurance department: QAI provided. Reporter's information added. Narrative was amended accordingly.  Company comment: Skin laceration and syringe issue were associated with the use of Afluria Quadrivalent. Causality is assessed as unrelated for skin laceration since the injury was a result of broken glass of syringe. Syringe issue is also assessed as unrelated to Afluria Quadrivalent, per company's conventions. 'Laceration of thumb' and 'syringe broken' are assessed as related to device luer lok.; Sender's Comments: Skin laceration and syringe issue were associated with the use of Afluria Quadrivalent. Causality is assessed as unrelated for skin laceration since the injury was a result of broken glass of syringe. Syringe issue is also assessed as unrelated to Afluria Quadrivalent, per company's conventions. 'Laceration of thumb' and 'syringe broken' are assessed as related to device luer lok.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Bladder irritation, Bladder pain, Haemorrhage, Thrombosis
Clinical narrative: Bladder irritation two days after first shot.  Some blood tinge.  Resolved in a few days.   Significant bladder pain, bleeding, incl clots  two days after second shot.  Resolved with cranberry pills after a few days. Thought maybe was due to eating jalapena peppers in my chicken nachoes. Both weekends. Then heard that women are reporting bizarre bleeding after vaccination so re evaluated and considered the bleeding could have been an adverse reaction to vaccine and decided to report my experience.
Age: 19.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Cold sweat, Dizziness, Flushing, Pallor
Clinical narrative: At approximately 4:15 PM, a pt stated feeling light-headed and clammy.  Pt was assisted to a wheelchair and moved to a cot.  Pt's vital were assessed. HR:120, RR:20, SaO2: 98.  Ot appeared flushing and pale.  Lung sound were clear and equal bilaterally.  Pt sat for 30 minutes and stated she wanted to go to the hospital POV.  Pt's VS were reassessed.  HR: 106, BP: 136/86, RR: 20, SaO2: 98%.  Pt signed  form.  Pt was assisted out of the clinic by wheelchair.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Feeling hot, Hyperhidrosis, Loss of consciousness
Clinical narrative: Prior to vaccination the patient reported that in the past he had passed out after giving blood. About a minute after administering the COVID-19 vaccine the patient reported feeling dizzy. He then passed out in the chair. We safely moved the patient to the floor. Then within approximately 15 seconds the patient sat up and then stood up on his own. We asked the patient to then be seated in the chair while he recovered. We called 911 as soon as he passed out. Patient was somewhat confused initially but quickly regained his bearings. He began sweating and said he was very hot. We checked his blood pressure and it was 100/80. Patient continued to recover and said he was feeling better. We had him wait until EMTs arrived. He told them he did not need any care. We took his blood pressure again and it was now 110/75. He said he felt well to go to the EMTs and pharmacist.
Age: 30.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: In January I started complaining to my husband about a noise at night - low hum. I thought it was related to our home (freezer, pipes, gas, etc), but my husband couldn?t here it.  The sound persisted, and I noticed it also when we stayed elsewhere so I then recognized it as tinnitus.   Interestingly, after my husband got his covid vaccine he started to have tinnitus as well, so we began to question if this is a side effect of the vaccine.  It is now May, and my tinnitus persists.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Wheezing
Clinical narrative: Pt developed wheezing and coughing due to wheezing, pt attempted puffs from her personal albuterol inhaler with no relief, an albuterol neb was administered and 50mg benadryl given IM, pts symptoms resolved with this treatment, total time was approximately 15-20 minutes.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain
Clinical narrative: Extreme body aches Fatigue
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Hypoaesthesia oral, Paraesthesia, Paraesthesia oral, Pharyngeal swelling
Clinical narrative: Patient complained of tongue and jaw feeling "numb and tingly". Vital signs stable. Numbness resolved but throat feels slightly swollen. No wheezing, or difficulty breathing, speaking in full sentences. Doctor onsite consulted. Patient observed for additional 30 minutes. Symptoms resolved. Discharged from clinic with doctor's approval.
Age: 25.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Vision blurred
Clinical narrative: Pt, reported having blurry vision and dizziness denies SOB, dyspnea or itchiness and was instructed to put  head dawn and encouraged to drink water and pt has no other co-morbidities but stated he was nervous to first dose, after a few minutes pt felt better and symptoms subsided. instructed to finish 15 min observation time and to notify team if symptoms return or worsen.
Age: 23.0
Sex: M
Vaccine: COVID19
Symptoms: Cold sweat, Headache, Seizure like phenomena, Vomiting
Clinical narrative: Patient presented @ 1356 hrs in observation area. Patient was sitting in chair. Observed patients' head tilt backwards. Care initiated with head/neck support. Patient began seizure like activity lasting approx. 1 minute. Patient transferred to floor for protection. Upon exam Patient was AAO x 2, skin: cool/clamy. Patient began c/o headache and denied any past medical history. Transferred patient to cot for evaluation. VS: HR:92,RR:20,BP:106/64. Patient began vomiting during evaluation. Post vomiting patient said he felt fine. EMS on scene and care transferred to ED.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Musculoskeletal stiffness, Tinnitus
Clinical narrative: Tinnitus, Pain/Stiffness in Shoulder
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia, Swelling face
Clinical narrative: Tingling sensation in tongue and face. Reports swelling to left side of face with most evident swelling being to lips, cheek and eye lid. Denies any difficulty breathing or swallowing. All symptoms resolved within 24 hours, used OTC Benedryl
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Anaemia, Confusional state, Disturbance in attention, Dizziness, Fatigue
Clinical narrative: 3 days of severe fatigue, dizzy w/ change of position, feeling of her head spinning when getting out of bed or up from a chair & sometimes when sitting. "feeling confused, trouble concentrating, very tired". Hands feeling cold, not tingling.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Full blood count abnormal, Haematocrit decreased, Haemoglobin decreased, Metabolic function test, Nystagmus
Clinical narrative: 3 days of severe fatigue, dizzy w/ change of position, feeling of her head spinning when getting out of bed or up from a chair & sometimes when sitting. "feeling confused, trouble concentrating, very tired". Hands feeling cold, not tingling.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Orthostatic hypotension, Platelet count normal, Vertigo, White blood cell count normal
Clinical narrative: 3 days of severe fatigue, dizzy w/ change of position, feeling of her head spinning when getting out of bed or up from a chair & sometimes when sitting. "feeling confused, trouble concentrating, very tired". Hands feeling cold, not tingling.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Flushing, Paraesthesia, Paraesthesia oral, Pharyngeal paraesthesia
Clinical narrative: Within 15 min of vaccine face flushed, felt a little light headed, and felt tingling in jaw/mouth/throat. Intermittently worse and a little better. Was on way home from store and had to return. Ended up seeing doctor. Was given 2 Benadryl and told to monitor and not receive second shot.
Age: 87.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Death
Clinical narrative: May 3, 2021, received a call from healthcare provider where the vaccine was given by healthcare provider. COVID 19 Prescreening Form Completed and Vaccine given 4/23/2021. Patient waited 15 minutes post vaccination no reaction.  Her family also received a vaccine. Daughter and Son-In Law. Received a call that patient had died on 5/2/2021. Presented to healthcare facility for chest pain according to healthcare provider.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Breast pain, Dizziness, Injection site pain, Palpitations, Syncope
Clinical narrative: I fainted at the facility I was at 10 minutes after the shot. I've since had burning at the injection shot (daily,  months later) and a  pain in the left side of my breast. I am often dizzy with the ground feeling like it's moving. I fainted a second time after a dizzy spell a few weeks after the second shot/fainting episode. My heart is often racing post getting the vaccine.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Cerebrovascular accident
Clinical narrative: Stroke on the left side of the brain, evolved temporal
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Electrocardiogram, Fatigue, Headache, Myalgia, Pain
Clinical narrative: Instantly I felt pain my arm hurt which was kinda weird through the day I felt tired bad headache took Advil it did not go away also took extrin  next day had 102 fever and had pain in the head achy, arm hurt, muscle hurt  this went on for the whole week, I stayed in bed the whole week on sat i thought i had covid so i went to Dr and got a test the test was negative the did an ekg  shot a toroidal which is a pain med for headach the pain they asked me to go the er but i wanted to wait it out  these same symptoms continued
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Pyrexia, SARS-CoV-2 test negative
Clinical narrative: Instantly I felt pain my arm hurt which was kinda weird through the day I felt tired bad headache took Advil it did not go away also took extrin  next day had 102 fever and had pain in the head achy, arm hurt, muscle hurt  this went on for the whole week, I stayed in bed the whole week on sat i thought i had covid so i went to Dr and got a test the test was negative the did an ekg  shot a toroidal which is a pain med for headach the pain they asked me to go the er but i wanted to wait it out  these same symptoms continued
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus got louder
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Alanine aminotransferase normal, Albumin globulin ratio normal, Aspartate aminotransferase normal, Basophil percentage decreased, Bilirubin conjugated
Clinical narrative: Patient is a 17 yo male with no hx asthma who presented to medical center ED as transfer from facility with pleuritic chest pain and fever x1 day. Recent history of second covid vaccine on Friday (5/14). Patient reported associated fatigue, headache and muscle aches late Friday into Saturday (5/15). Sunday patient reported a fever (101 F) and chest pain with deep inspiration. No associated SOB, increased work of breathing or abdominal pain. Was seen initially at urgent care and then referred to facility for "an abnormal EKG."    Pertinent findings at facility: troponin 0.31, EKG wnl, rapid covid negative, ESR 9, CK 134, D-dimer <150, WBC 12.4 w/ left shift. Transferred to medical center for further workup.   While in medical center ED, troponin 1.59. EKG rSR' leads V1-V3 w/o ST segment elevation. MISC tier 1 studies drawn. Cardiology consulted - admit for observation, myocarditis infectious workup, echocardiogram and  During his time in the ED, patient continued to have pain with deep inspiration as well as when he had to yawn. He other wise felt fine. Vital signs normal throughout out time in ED.  His troponin continued to rise, with max of 14, so decision was made to start IVIG and steroids. His troponin fell over the next day. He remained stable from a clinical standpoint, and symptoms had resolved by the morning of 5/18. At time of filing, patient is still hospitalized at medical center, with further labs and imaging pending.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Blood albumin normal, Blood alkaline phosphatase normal, Blood bilirubin normal, Blood chloride normal, Blood creatine phosphokinase MB increased
Clinical narrative: Patient is a 17 yo male with no hx asthma who presented to medical center ED as transfer from facility with pleuritic chest pain and fever x1 day. Recent history of second covid vaccine on Friday (5/14). Patient reported associated fatigue, headache and muscle aches late Friday into Saturday (5/15). Sunday patient reported a fever (101 F) and chest pain with deep inspiration. No associated SOB, increased work of breathing or abdominal pain. Was seen initially at urgent care and then referred to facility for "an abnormal EKG."    Pertinent findings at facility: troponin 0.31, EKG wnl, rapid covid negative, ESR 9, CK 134, D-dimer <150, WBC 12.4 w/ left shift. Transferred to medical center for further workup.   While in medical center ED, troponin 1.59. EKG rSR' leads V1-V3 w/o ST segment elevation. MISC tier 1 studies drawn. Cardiology consulted - admit for observation, myocarditis infectious workup, echocardiogram and  During his time in the ED, patient continued to have pain with deep inspiration as well as when he had to yawn. He other wise felt fine. Vital signs normal throughout out time in ED.  His troponin continued to rise, with max of 14, so decision was made to start IVIG and steroids. His troponin fell over the next day. He remained stable from a clinical standpoint, and symptoms had resolved by the morning of 5/18. At time of filing, patient is still hospitalized at medical center, with further labs and imaging pending.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Blood creatine phosphokinase increased, Blood lactate dehydrogenase increased, Blood magnesium, Blood phosphorus normal, Blood potassium normal
Clinical narrative: Patient is a 17 yo male with no hx asthma who presented to medical center ED as transfer from facility with pleuritic chest pain and fever x1 day. Recent history of second covid vaccine on Friday (5/14). Patient reported associated fatigue, headache and muscle aches late Friday into Saturday (5/15). Sunday patient reported a fever (101 F) and chest pain with deep inspiration. No associated SOB, increased work of breathing or abdominal pain. Was seen initially at urgent care and then referred to facility for "an abnormal EKG."    Pertinent findings at facility: troponin 0.31, EKG wnl, rapid covid negative, ESR 9, CK 134, D-dimer <150, WBC 12.4 w/ left shift. Transferred to medical center for further workup.   While in medical center ED, troponin 1.59. EKG rSR' leads V1-V3 w/o ST segment elevation. MISC tier 1 studies drawn. Cardiology consulted - admit for observation, myocarditis infectious workup, echocardiogram and  During his time in the ED, patient continued to have pain with deep inspiration as well as when he had to yawn. He other wise felt fine. Vital signs normal throughout out time in ED.  His troponin continued to rise, with max of 14, so decision was made to start IVIG and steroids. His troponin fell over the next day. He remained stable from a clinical standpoint, and symptoms had resolved by the morning of 5/18. At time of filing, patient is still hospitalized at medical center, with further labs and imaging pending.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Blood sodium normal, Blood thyroid stimulating hormone increased, Blood urea normal, Bordetella test negative, C-reactive protein increased
Clinical narrative: Patient is a 17 yo male with no hx asthma who presented to medical center ED as transfer from facility with pleuritic chest pain and fever x1 day. Recent history of second covid vaccine on Friday (5/14). Patient reported associated fatigue, headache and muscle aches late Friday into Saturday (5/15). Sunday patient reported a fever (101 F) and chest pain with deep inspiration. No associated SOB, increased work of breathing or abdominal pain. Was seen initially at urgent care and then referred to facility for "an abnormal EKG."    Pertinent findings at facility: troponin 0.31, EKG wnl, rapid covid negative, ESR 9, CK 134, D-dimer <150, WBC 12.4 w/ left shift. Transferred to medical center for further workup.   While in medical center ED, troponin 1.59. EKG rSR' leads V1-V3 w/o ST segment elevation. MISC tier 1 studies drawn. Cardiology consulted - admit for observation, myocarditis infectious workup, echocardiogram and  During his time in the ED, patient continued to have pain with deep inspiration as well as when he had to yawn. He other wise felt fine. Vital signs normal throughout out time in ED.  His troponin continued to rise, with max of 14, so decision was made to start IVIG and steroids. His troponin fell over the next day. He remained stable from a clinical standpoint, and symptoms had resolved by the morning of 5/18. At time of filing, patient is still hospitalized at medical center, with further labs and imaging pending.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Carbon dioxide increased, Chest pain, Chlamydia test negative, Electrocardiogram abnormal, Enterovirus test
Clinical narrative: Patient is a 17 yo male with no hx asthma who presented to medical center ED as transfer from facility with pleuritic chest pain and fever x1 day. Recent history of second covid vaccine on Friday (5/14). Patient reported associated fatigue, headache and muscle aches late Friday into Saturday (5/15). Sunday patient reported a fever (101 F) and chest pain with deep inspiration. No associated SOB, increased work of breathing or abdominal pain. Was seen initially at urgent care and then referred to facility for "an abnormal EKG."    Pertinent findings at facility: troponin 0.31, EKG wnl, rapid covid negative, ESR 9, CK 134, D-dimer <150, WBC 12.4 w/ left shift. Transferred to medical center for further workup.   While in medical center ED, troponin 1.59. EKG rSR' leads V1-V3 w/o ST segment elevation. MISC tier 1 studies drawn. Cardiology consulted - admit for observation, myocarditis infectious workup, echocardiogram and  During his time in the ED, patient continued to have pain with deep inspiration as well as when he had to yawn. He other wise felt fine. Vital signs normal throughout out time in ED.  His troponin continued to rise, with max of 14, so decision was made to start IVIG and steroids. His troponin fell over the next day. He remained stable from a clinical standpoint, and symptoms had resolved by the morning of 5/18. At time of filing, patient is still hospitalized at medical center, with further labs and imaging pending.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Eosinophil percentage decreased, Fatigue, Full blood count, Gamma-glutamyltransferase normal, Globulins decreased
Clinical narrative: Patient is a 17 yo male with no hx asthma who presented to medical center ED as transfer from facility with pleuritic chest pain and fever x1 day. Recent history of second covid vaccine on Friday (5/14). Patient reported associated fatigue, headache and muscle aches late Friday into Saturday (5/15). Sunday patient reported a fever (101 F) and chest pain with deep inspiration. No associated SOB, increased work of breathing or abdominal pain. Was seen initially at urgent care and then referred to facility for "an abnormal EKG."    Pertinent findings at facility: troponin 0.31, EKG wnl, rapid covid negative, ESR 9, CK 134, D-dimer <150, WBC 12.4 w/ left shift. Transferred to medical center for further workup.   While in medical center ED, troponin 1.59. EKG rSR' leads V1-V3 w/o ST segment elevation. MISC tier 1 studies drawn. Cardiology consulted - admit for observation, myocarditis infectious workup, echocardiogram and  During his time in the ED, patient continued to have pain with deep inspiration as well as when he had to yawn. He other wise felt fine. Vital signs normal throughout out time in ED.  His troponin continued to rise, with max of 14, so decision was made to start IVIG and steroids. His troponin fell over the next day. He remained stable from a clinical standpoint, and symptoms had resolved by the morning of 5/18. At time of filing, patient is still hospitalized at medical center, with further labs and imaging pending.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: HIV test, Haematocrit normal, Haemoglobin normal, Headache, Hepatitis B antibody negative
Clinical narrative: Patient is a 17 yo male with no hx asthma who presented to medical center ED as transfer from facility with pleuritic chest pain and fever x1 day. Recent history of second covid vaccine on Friday (5/14). Patient reported associated fatigue, headache and muscle aches late Friday into Saturday (5/15). Sunday patient reported a fever (101 F) and chest pain with deep inspiration. No associated SOB, increased work of breathing or abdominal pain. Was seen initially at urgent care and then referred to facility for "an abnormal EKG."    Pertinent findings at facility: troponin 0.31, EKG wnl, rapid covid negative, ESR 9, CK 134, D-dimer <150, WBC 12.4 w/ left shift. Transferred to medical center for further workup.   While in medical center ED, troponin 1.59. EKG rSR' leads V1-V3 w/o ST segment elevation. MISC tier 1 studies drawn. Cardiology consulted - admit for observation, myocarditis infectious workup, echocardiogram and  During his time in the ED, patient continued to have pain with deep inspiration as well as when he had to yawn. He other wise felt fine. Vital signs normal throughout out time in ED.  His troponin continued to rise, with max of 14, so decision was made to start IVIG and steroids. His troponin fell over the next day. He remained stable from a clinical standpoint, and symptoms had resolved by the morning of 5/18. At time of filing, patient is still hospitalized at medical center, with further labs and imaging pending.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Hepatitis C virus test, Human metapneumovirus test, Human rhinovirus test, Immunoglobulin therapy, Influenza A virus test negative
Clinical narrative: Patient is a 17 yo male with no hx asthma who presented to medical center ED as transfer from facility with pleuritic chest pain and fever x1 day. Recent history of second covid vaccine on Friday (5/14). Patient reported associated fatigue, headache and muscle aches late Friday into Saturday (5/15). Sunday patient reported a fever (101 F) and chest pain with deep inspiration. No associated SOB, increased work of breathing or abdominal pain. Was seen initially at urgent care and then referred to facility for "an abnormal EKG."    Pertinent findings at facility: troponin 0.31, EKG wnl, rapid covid negative, ESR 9, CK 134, D-dimer <150, WBC 12.4 w/ left shift. Transferred to medical center for further workup.   While in medical center ED, troponin 1.59. EKG rSR' leads V1-V3 w/o ST segment elevation. MISC tier 1 studies drawn. Cardiology consulted - admit for observation, myocarditis infectious workup, echocardiogram and  During his time in the ED, patient continued to have pain with deep inspiration as well as when he had to yawn. He other wise felt fine. Vital signs normal throughout out time in ED.  His troponin continued to rise, with max of 14, so decision was made to start IVIG and steroids. His troponin fell over the next day. He remained stable from a clinical standpoint, and symptoms had resolved by the morning of 5/18. At time of filing, patient is still hospitalized at medical center, with further labs and imaging pending.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Influenza B virus test, Influenza virus test, Liver function test normal, Lymphocyte percentage, Mean cell haemoglobin concentration
Clinical narrative: Patient is a 17 yo male with no hx asthma who presented to medical center ED as transfer from facility with pleuritic chest pain and fever x1 day. Recent history of second covid vaccine on Friday (5/14). Patient reported associated fatigue, headache and muscle aches late Friday into Saturday (5/15). Sunday patient reported a fever (101 F) and chest pain with deep inspiration. No associated SOB, increased work of breathing or abdominal pain. Was seen initially at urgent care and then referred to facility for "an abnormal EKG."    Pertinent findings at facility: troponin 0.31, EKG wnl, rapid covid negative, ESR 9, CK 134, D-dimer <150, WBC 12.4 w/ left shift. Transferred to medical center for further workup.   While in medical center ED, troponin 1.59. EKG rSR' leads V1-V3 w/o ST segment elevation. MISC tier 1 studies drawn. Cardiology consulted - admit for observation, myocarditis infectious workup, echocardiogram and  During his time in the ED, patient continued to have pain with deep inspiration as well as when he had to yawn. He other wise felt fine. Vital signs normal throughout out time in ED.  His troponin continued to rise, with max of 14, so decision was made to start IVIG and steroids. His troponin fell over the next day. He remained stable from a clinical standpoint, and symptoms had resolved by the morning of 5/18. At time of filing, patient is still hospitalized at medical center, with further labs and imaging pending.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Mean cell haemoglobin normal, Mean cell volume, Mean platelet volume normal, Monocyte percentage, Myalgia
Clinical narrative: Patient is a 17 yo male with no hx asthma who presented to medical center ED as transfer from facility with pleuritic chest pain and fever x1 day. Recent history of second covid vaccine on Friday (5/14). Patient reported associated fatigue, headache and muscle aches late Friday into Saturday (5/15). Sunday patient reported a fever (101 F) and chest pain with deep inspiration. No associated SOB, increased work of breathing or abdominal pain. Was seen initially at urgent care and then referred to facility for "an abnormal EKG."    Pertinent findings at facility: troponin 0.31, EKG wnl, rapid covid negative, ESR 9, CK 134, D-dimer <150, WBC 12.4 w/ left shift. Transferred to medical center for further workup.   While in medical center ED, troponin 1.59. EKG rSR' leads V1-V3 w/o ST segment elevation. MISC tier 1 studies drawn. Cardiology consulted - admit for observation, myocarditis infectious workup, echocardiogram and  During his time in the ED, patient continued to have pain with deep inspiration as well as when he had to yawn. He other wise felt fine. Vital signs normal throughout out time in ED.  His troponin continued to rise, with max of 14, so decision was made to start IVIG and steroids. His troponin fell over the next day. He remained stable from a clinical standpoint, and symptoms had resolved by the morning of 5/18. At time of filing, patient is still hospitalized at medical center, with further labs and imaging pending.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Mycoplasma test negative, N-terminal prohormone brain natriuretic peptide increased, Neutrophil count, Platelet count normal, Pleuritic pain
Clinical narrative: Patient is a 17 yo male with no hx asthma who presented to medical center ED as transfer from facility with pleuritic chest pain and fever x1 day. Recent history of second covid vaccine on Friday (5/14). Patient reported associated fatigue, headache and muscle aches late Friday into Saturday (5/15). Sunday patient reported a fever (101 F) and chest pain with deep inspiration. No associated SOB, increased work of breathing or abdominal pain. Was seen initially at urgent care and then referred to facility for "an abnormal EKG."    Pertinent findings at facility: troponin 0.31, EKG wnl, rapid covid negative, ESR 9, CK 134, D-dimer <150, WBC 12.4 w/ left shift. Transferred to medical center for further workup.   While in medical center ED, troponin 1.59. EKG rSR' leads V1-V3 w/o ST segment elevation. MISC tier 1 studies drawn. Cardiology consulted - admit for observation, myocarditis infectious workup, echocardiogram and  During his time in the ED, patient continued to have pain with deep inspiration as well as when he had to yawn. He other wise felt fine. Vital signs normal throughout out time in ED.  His troponin continued to rise, with max of 14, so decision was made to start IVIG and steroids. His troponin fell over the next day. He remained stable from a clinical standpoint, and symptoms had resolved by the morning of 5/18. At time of filing, patient is still hospitalized at medical center, with further labs and imaging pending.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Protein total normal, Pyrexia, Red blood cell count normal, Red blood cell sedimentation rate increased, Red blood cell sedimentation rate normal
Clinical narrative: Patient is a 17 yo male with no hx asthma who presented to medical center ED as transfer from facility with pleuritic chest pain and fever x1 day. Recent history of second covid vaccine on Friday (5/14). Patient reported associated fatigue, headache and muscle aches late Friday into Saturday (5/15). Sunday patient reported a fever (101 F) and chest pain with deep inspiration. No associated SOB, increased work of breathing or abdominal pain. Was seen initially at urgent care and then referred to facility for "an abnormal EKG."    Pertinent findings at facility: troponin 0.31, EKG wnl, rapid covid negative, ESR 9, CK 134, D-dimer <150, WBC 12.4 w/ left shift. Transferred to medical center for further workup.   While in medical center ED, troponin 1.59. EKG rSR' leads V1-V3 w/o ST segment elevation. MISC tier 1 studies drawn. Cardiology consulted - admit for observation, myocarditis infectious workup, echocardiogram and  During his time in the ED, patient continued to have pain with deep inspiration as well as when he had to yawn. He other wise felt fine. Vital signs normal throughout out time in ED.  His troponin continued to rise, with max of 14, so decision was made to start IVIG and steroids. His troponin fell over the next day. He remained stable from a clinical standpoint, and symptoms had resolved by the morning of 5/18. At time of filing, patient is still hospitalized at medical center, with further labs and imaging pending.